Quotables
"That’s an amazing invention, but who would ever want to use one of them?"
President Rutherford B. Hayes ; Said in 1876, after Alexander Graham Bell demonstrated the telephone to him at the White House
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 6867181 | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides A method of spherifying a sustained release ionic conjugate which contains a free carboxyl group-containing polymer and a free amino group-containing drug which are ionically bonded to each other. ... | 03/15/2005 |
| 6423334 | Composition and method for enhancing transport across gastrointestinal tract cell layers A composition for enteral administration having a non-ionic vegetable oil GIT absorption enhancer capable of increasing the enteral absorbability of drugs, especially oral absorbability of hydrophilic and macromolecular drugs. The non-ionic vegetable oil ... | 07/23/2002 |
| 6312709 | Seaweed supplement diet for enhancing immune response in mammals and poultry Seaweed supplement is included in diet of mammals and poultry to enhance immune response. In one embodiment, pasture forage is treated with seaweed supplement. When cattle or lambs are grazed on seaweed supplement treated endophyte-infected forage, immune... | 11/06/2001 |
| 6228836 | Permucous preparation A composition for permucosal administration characterized by containing Antago-3 or a physiologically acceptable salt thereof, and a sucrose fatty acid ester. With the composition for permucosal administration of the invention there is provided a long-ter... | 05/08/2001 |
| 6221958 | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides Disclosed is a sustained release pharmaceutical composition. The composition includes a polyester containing a free COOH group ionically conjugated with a bioactive polypeptide comprising at least one effective ionogenic amine, wherein at least 50% by wei... | 04/24/2001 |
| 6086918 | Oral peptide pharmaceutical products Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine by virtue of an acid-resistant protective vehicle which transports components of the ... | 07/11/2000 |
| 6034175 | Salts of peptides with carboxy-terminated polyesters This invention relates to novel salts composed of a cation derived from a peptide containing at least one basic group and an anion derived from a carboxy-terminated polyester, processes for the manufacture of such salts, and the use of such salts in the m... | 03/07/2000 |
| 5976569 | Diketopiperazine-based delivery systems Compositions useful in the delivery of active agents are provided. These delivery compositions include (a) an active agent; and either (b)(1) a carrier of (i) at least one amino acid and (ii) at least one diketopiperazine or (b)(2) at least one mono-N-sub... | 11/02/1999 |
| 5948825 | Microemulsion preparation containing a slightly absorbable substance Microemulsion preparation in which a plurality of specified surfactants are combined such that aqueous-phase droplets that contain a physiologically active substance of low absorption and which have an average size of 0.4-100 nm are dispersed in an oil-ph... | 09/07/1999 |
| 5889110 | Salts of peptides with carboxy-terminated polyesters This invention relates to novel salts composed of a cation derived from a peptide containing at least one basic group and an anion derived from a carboxy-terminated polyester, processes for the manufacture of such salts, and the use of such salts in the m... | 03/30/1999 |
| 5863985 | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides Disclosed is a sustained release pharmaceutical composition. The composition includes a polyester containing a free COOH group ionically conjugated with a bioactive polypeptide comprising at least one effective ionogenic amine, wherein at least 50% by wei... | 01/26/1999 |
| 5780434 | Composition for oral administration of peptides A solid pharmaceutical composition for oral administration of small and medium size peptides, particularly vasopressin, oxytocin, and their analogues, comprises the peptide, a protease inhibitor, an enteric coat and a pharmaceutically acceptable carrier c... | 07/14/1998 |
| 5698516 | Biologically active vasopressin analogues Vasopressin analogues of formula (I) ##STR1## wherein X is (S)-2-amino-2-methyl-butanoic acid (CaMeAbu) or Valine (Val), Y is Thienylalanine (Thi) or Methionine (Met), Z is D-Phenylalanine (D-Phe) or D-Thienylalanine (Thi) or D-Tyrosine (D-Tyr), are ... | 12/16/1997 |
| 5693338 | Diketopiperazine-based delivery systems Compositions useful in the delivery of active agents are provided. These delivery compositions include (a) an active agent; and either (b)(1) a carrier of (i) at least one amino acid and (ii) at least one diketopiperazine or (b)(2) at least one mono-N-sub... | 12/02/1997 |
| 5672659 | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides A composition including a polyester containing one or more free COOH groups ionically conjugated with a bioactive polypeptide comprising at least one effective ionogenic amine, wherein the polyester contains a member selected from the group of L-lactic ac... | 09/30/1997 |
| 5618791 | Memory enhancing peptides The invention is a class of memory enhancing peptides having the general formula: R1 --Asn--X1 --X2 --X3 --R2 where R1 =pyroglutamyl, acetyl, H, peptidyl X1 =Ala, Ile, Leu, Tyr, Phe, Val, ... | 04/08/1997 |
| 5451569 | Pulmonary drug delivery system The present invention provides a method of improving the efficiency of absorption into the bloodstream of drugs delivered through the pulmonary route. The drug is mixed with surfactant, preferably a surfactant naturally produced by the lung. This method i... | 09/19/1995 |
| 5356904 | Carbostyril oxytocin receptor antagonists A method of inhibiting oxytocin from acting at its receptor site by administering oxytocin receptor antagonist compounds of the formula ##STR1## wherein X is oxygen or sulfur; Y is hydrogen or lower alkyl; RA is ##STR2##... | 10/18/1994 |
| 5122371 | Biologically active agent having antihypertensive activity in mammals A biologically active agent extracted from female breast cyst fluids displays anti-hypertensive activity in mammals. The agent is also useful in the treatment of congestive heart disease, artial fibrillation and idiopathic edema in mammals.... | 06/16/1992 |
| 5095003 | Oxytocin and vasopressin antagonists Cyclic peptides are produced by the controlled aerobic fermentation of Streptomyces silvensis, ATTCC No. 53525 or ATCC No. 53526. These compounds are antagonists of oxytocin and are useful in the treatment of preterm labor and vasopressin and are thus use... | 03/10/1992 |
| 5055448 | Linear derivatives of arginine vasopressin antagonists Compounds acting as antagonists of the antidiuretic/and or vasopressor activity of arginine vasopressin are those of the formula A--CH2 CO--D--Tyr(R)--Phe--Y--Asn--T--U--Z--Q wherein A is a-adamantyl, cyclohexyl, cyclopentyl, 1-mercaptocyclohexyl, 1... | 10/08/1991 |
| 5047398 | DDAVP antidiuretic and method therefor There is disclosed, in one aspect, an antidiuretic composition in oral dosage form for humans. This composition comprises an antidiuretically effective amount of 1-deamino-8-D-arginine vasopressin (DDAVP) and a pharmaceutically acceptable carrier. The com... | 09/10/1991 |
| 5028438 | Biologically active agent having anti-hypertensive activity in mammals A biologically active agent extracted from female breast cyst fluids displays anti-hypertensive activity in mammals. The agent is also useful in the treatment of congestive heart disease, atrial fibrillation and idiopathic edema in mammals.... | 07/02/1991 |
| 4950650 | Novel arginine vasopressin-binding peptides The invention concerns novel AVP-binding peptides having the formula: Thr-Met-X-Val-Leu-Thr-Gly-Ser-Pro-B wherein X is selected from the group consisting of Lys, Arg, and Asp; B is OH, NH2, NHAlK, wherein Alk is lower alkyl of 1-4 carbons, inclusive. ... | 08/21/1990 |
| 4829051 | N-substituted derivatives of 1-desaminovasopressin Novel analogs of biologically active vasopressin and its synthetic analogs having improved activity are represented by the structural formula: ##STR1## wherein A hydrogen; is hydroxy or lower alkoxy, especially methoxy, B is the peptide residue of ph... | 05/09/1989 |
| 4826813 | 4'-Methyl-ଲ-mercapto-ଲ,ଲ-cyclopentamethylenepropionic acid vasopressin antagonists Vasopressin antagonists which have a 4'-methyl-ଲ-mercapto-ଲ,ଲ-cyclopentamethylenepropionic acid group have vasopressin antagonist activity without substantial agonist activity. A species of the invention is [1-(4'-methyl-ଲ-mer... | 05/02/1989 |
| 4786631 | Novel arginine vasopressin-binding peptides The invention concerns novel AVP-binding peptides having the formula: wherein X is selected from the group consisting of Lys, Arg, and Asp; B is OH, NH2, NHAlk, wherein Alk is lower alkyl of 1-4 carbons, inclusive. These peptides block AVP function,... | 11/22/1988 |
| 4772586 | Novel derivatives of arginine vasopressin antagonists Compounds acting as antagonists of the antidiuretic/and or vasopressor activity of arginine vasopressin are those of the formula ##STR1## wherein n is 4 or 5; X is (D- or L-)Tyr(R), D-Phe, D-Val, D-Leu, D-Ile, D-Nva, D-Nle, D-Cha, D-Abu, D-Thr, D-Asn... | 09/20/1988 |
| 4766108 | Tyr-Arg-vasopressin antagonists Vasopressin antagonists which have a dipeptide tail composed of a neutral and basic amino acid unit demonstrate potent V1 and V2 -antagonist activity. Two species of this invention, which are prepared by solid phase peptide synthesis... | 08/23/1988 |
| 4760052 | 1,6-dicarba-vasopressin compounds New compounds which have potent V2 -vasopressin antagonistic activity are prepared by a 1,6-cyclization using peptide bond formation. The structures of the compounds are characterized by a Pas1,6 or Tas1,6 cyclized unit. A... | 07/26/1988 |
| 4742154 | GLN- or ASN-vasopressin compounds Peptides whose structures resemble those of vasopressin antagonists but have both a carboxamido amino acid unit and a basic amino acid unit in the side chain have good antagonist activity. A species of the invention is [1-(ଲ-mercapto-ଲ,ଲ... | 05/03/1988 |
| 4724229 | Arg-arg-arg-vasopressin antagonists Vasopressin antagonists which have a tripeptide side chain comprised of three basic amino acids, such as arginine, lysine or ornithine, demonstrate potent V1 and V2 -antagonist activity. A species of the invention, which is prepared ... | 02/09/1988 |
| 4717715 | ARG7 -ARG8 -vasopressin antagonists Vasopressin antagonists which have a dipeptide side chain comprised of two basic amino acids demonstrate potent V1 and V2 -antagonist activity. A species of the invention, which is prepared by conventional peptide sequencing, is ... | 01/05/1988 |
| 4714696 | Novel derivatives of arginine vasopressin antagonists Compounds acting as antagonists of the antidiuretic/and or vasopressor activity of arginine vasopressin are those of the formula ##STR1## wherein n is 4 or 5; X is (D- or L-)Tyr(R), D-Phe, D-Val, D-Leu, D-Ile, D-Nva, D-Nle, D-Cha, D-Abu, D-Thr, D-Asn... | 12/22/1987 |
| 4711877 | 6-pen-vasopressin compounds Vasopressin derivatives having unexpected VSP site binding activity whose structures are characterized by a Mpr unit at position 1 and a Pen unit at position 6 are prepared by standard peptide synthetic methods also using an oxidative cyclization of a lin... | 12/08/1987 |
| 4687758 | Des-proline-N-methylarginine vasopressins Peptides having vasopressin antagonist activity are prepared by a peptide synthesizer to insert a N-methylarginine at the 7-position of the structure. An example of this series of compounds is [1-(ଲ-mercapto-ଲ,ଲ-cyclopentamethylenepropio... | 08/18/1987 |
| 4670419 | Pharmaceutical composition and its rectal use A pharmaceutical composition containing a hydrophilic drug which is poorly absorbable through the gastrointestinal tract, and cyclodextrin, increases the absorbability of the drug into the mammalian body when administered by a non-oral or non-injection ro... | 06/02/1987 |
| 4658013 | Analgesic and/or opiate antagonist tripeptide amides and processes for preparation and compositions thereof A genus of tripeptide amides and fifteen species thereof of Examples 4-18, which are useful as analgesics and/or opiate antagonists, three processes for preparation thereof, pharmaceutical compositions thereof, and the three tripeptide amide species of Ex... | 04/14/1987 |
| 4658015 | Polypeptide intermediates Certain vasopressin-like peptides, which have an acyclic unit at position 1 and which have an ω-amino- or guanidinoalkyl substituent attached to the cysteine in the 6-position of the ring, have V1 -vasopressin and oxytocin antagonist activity.... | 04/14/1987 |
| 4649130 | Novel derivatives of arginine vasopressin antagonists Compounds acting as antagonists of the antidiuretic/and or vasopressor activity of arginine vasopressin are those of the formula ##STR1## wherein n is 4 or 5; X is (D- or L-)Tyr(R), D-Phe, D-Val, D-Leu, D-lle, D-Nva, D-Nle, D-Cha, D-Abu, D-Thr, D-Asn... | 03/10/1987 |
